Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion

Yoon Hee Chun, SangHoon Ahn, Junyong Park, doyoung kim, KwangHyub Han, Chaeyoon Chon, Sun Jeong Byun, Seungup Kim

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The prognosis and treatment outcomes of hepatocellular carcinoma (HCC) with inferior vena cava (IVC)/heart invasion have not been established. This study aimed to investigate the clinical characteristics and treatment outcomes of patients with HCC extending to IVCIheart and ascertained whether active treatment beyond best supportive care (BSC) can prolong overall survival. Patients and Methods: We retrospectively reviewed 50 patients with HCC extending to IVC/heart who were admitted from November 1987 to November 2010. They were stratified into a control group with BSC alone (n=18) and a treated group with active treatment more than BSC (n=32). Results: The mean age was 56.5 years and male gender predominated (n=39, 78.0%). Treatment modalities in the treated group included systemic chemotherapy using 5-fluorouracil with/without cisplatin (n=10, 31.3%), transarterial chemoembolization (n=8, 25.0%), intra-arterial chemotherapy (n=3, 9.4%), concurrent chemoradiation therapy (n=3, 9.4%), radiation (n=2, 6.2%), surgery (n=1, 3.1%), and of the combination above (n=5, 15.6%). Active treatment more than BSC was the only independent predictor of overall survival and the overall survival of the treated group was significantly better than that of the control group (median 4.0 vs. 2.0 months, p=0.003). Conclusion: The prognosis of HCC with IVC/heart invasion is poor. However, if patients are cautiously selected, active treatment beyond BSC might provide a survival benefit in patients with HCC extending to IVC/heart.

Original languageEnglish
Pages (from-to)4641-4646
Number of pages6
JournalAnticancer Research
Volume31
Issue number12
Publication statusPublished - 2011 Dec 1

Fingerprint

Inferior Vena Cava
Hepatocellular Carcinoma
Survival
Therapeutics
Drug Therapy
Control Groups
Fluorouracil
Cisplatin
Radiation

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

@article{d95e1223322545efb4aca2705321eb91,
title = "Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion",
abstract = "Background: The prognosis and treatment outcomes of hepatocellular carcinoma (HCC) with inferior vena cava (IVC)/heart invasion have not been established. This study aimed to investigate the clinical characteristics and treatment outcomes of patients with HCC extending to IVCIheart and ascertained whether active treatment beyond best supportive care (BSC) can prolong overall survival. Patients and Methods: We retrospectively reviewed 50 patients with HCC extending to IVC/heart who were admitted from November 1987 to November 2010. They were stratified into a control group with BSC alone (n=18) and a treated group with active treatment more than BSC (n=32). Results: The mean age was 56.5 years and male gender predominated (n=39, 78.0{\%}). Treatment modalities in the treated group included systemic chemotherapy using 5-fluorouracil with/without cisplatin (n=10, 31.3{\%}), transarterial chemoembolization (n=8, 25.0{\%}), intra-arterial chemotherapy (n=3, 9.4{\%}), concurrent chemoradiation therapy (n=3, 9.4{\%}), radiation (n=2, 6.2{\%}), surgery (n=1, 3.1{\%}), and of the combination above (n=5, 15.6{\%}). Active treatment more than BSC was the only independent predictor of overall survival and the overall survival of the treated group was significantly better than that of the control group (median 4.0 vs. 2.0 months, p=0.003). Conclusion: The prognosis of HCC with IVC/heart invasion is poor. However, if patients are cautiously selected, active treatment beyond BSC might provide a survival benefit in patients with HCC extending to IVC/heart.",
author = "Chun, {Yoon Hee} and SangHoon Ahn and Junyong Park and doyoung kim and KwangHyub Han and Chaeyoon Chon and Byun, {Sun Jeong} and Seungup Kim",
year = "2011",
month = "12",
day = "1",
language = "English",
volume = "31",
pages = "4641--4646",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. / Chun, Yoon Hee; Ahn, SangHoon; Park, Junyong; kim, doyoung; Han, KwangHyub; Chon, Chaeyoon; Byun, Sun Jeong; Kim, Seungup.

In: Anticancer Research, Vol. 31, No. 12, 01.12.2011, p. 4641-4646.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion

AU - Chun, Yoon Hee

AU - Ahn, SangHoon

AU - Park, Junyong

AU - kim, doyoung

AU - Han, KwangHyub

AU - Chon, Chaeyoon

AU - Byun, Sun Jeong

AU - Kim, Seungup

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background: The prognosis and treatment outcomes of hepatocellular carcinoma (HCC) with inferior vena cava (IVC)/heart invasion have not been established. This study aimed to investigate the clinical characteristics and treatment outcomes of patients with HCC extending to IVCIheart and ascertained whether active treatment beyond best supportive care (BSC) can prolong overall survival. Patients and Methods: We retrospectively reviewed 50 patients with HCC extending to IVC/heart who were admitted from November 1987 to November 2010. They were stratified into a control group with BSC alone (n=18) and a treated group with active treatment more than BSC (n=32). Results: The mean age was 56.5 years and male gender predominated (n=39, 78.0%). Treatment modalities in the treated group included systemic chemotherapy using 5-fluorouracil with/without cisplatin (n=10, 31.3%), transarterial chemoembolization (n=8, 25.0%), intra-arterial chemotherapy (n=3, 9.4%), concurrent chemoradiation therapy (n=3, 9.4%), radiation (n=2, 6.2%), surgery (n=1, 3.1%), and of the combination above (n=5, 15.6%). Active treatment more than BSC was the only independent predictor of overall survival and the overall survival of the treated group was significantly better than that of the control group (median 4.0 vs. 2.0 months, p=0.003). Conclusion: The prognosis of HCC with IVC/heart invasion is poor. However, if patients are cautiously selected, active treatment beyond BSC might provide a survival benefit in patients with HCC extending to IVC/heart.

AB - Background: The prognosis and treatment outcomes of hepatocellular carcinoma (HCC) with inferior vena cava (IVC)/heart invasion have not been established. This study aimed to investigate the clinical characteristics and treatment outcomes of patients with HCC extending to IVCIheart and ascertained whether active treatment beyond best supportive care (BSC) can prolong overall survival. Patients and Methods: We retrospectively reviewed 50 patients with HCC extending to IVC/heart who were admitted from November 1987 to November 2010. They were stratified into a control group with BSC alone (n=18) and a treated group with active treatment more than BSC (n=32). Results: The mean age was 56.5 years and male gender predominated (n=39, 78.0%). Treatment modalities in the treated group included systemic chemotherapy using 5-fluorouracil with/without cisplatin (n=10, 31.3%), transarterial chemoembolization (n=8, 25.0%), intra-arterial chemotherapy (n=3, 9.4%), concurrent chemoradiation therapy (n=3, 9.4%), radiation (n=2, 6.2%), surgery (n=1, 3.1%), and of the combination above (n=5, 15.6%). Active treatment more than BSC was the only independent predictor of overall survival and the overall survival of the treated group was significantly better than that of the control group (median 4.0 vs. 2.0 months, p=0.003). Conclusion: The prognosis of HCC with IVC/heart invasion is poor. However, if patients are cautiously selected, active treatment beyond BSC might provide a survival benefit in patients with HCC extending to IVC/heart.

UR - http://www.scopus.com/inward/record.url?scp=84855174099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855174099&partnerID=8YFLogxK

M3 - Article

C2 - 22199343

AN - SCOPUS:84855174099

VL - 31

SP - 4641

EP - 4646

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -